[{"address1": "15 Crosby Drive", "city": "Bedford", "state": "MA", "zip": "01730", "country": "United States", "phone": "781 357 4000", "fax": "781 275 7562", "website": "https://www.ocutx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and in Phase 1 clinical trials for the treatment of non-proliferative diabetic retinopathy; PAXTRAVA, a travoprost intracameral hydrogel, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and PAXTRAVA. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.", "fullTimeEmployees": 274, "companyOfficers": [{"maxAge": 1, "name": "Dr. Pravin U. Dugel M.D.", "age": 60, "title": "Executive Chairman, President & CEO", "yearBorn": 1964, "fiscalYear": 2024, "totalPay": 1487392, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jeffrey S. Heier M.D.", "age": 63, "title": "Chief Scientific Officer", "yearBorn": 1961, "fiscalYear": 2024, "totalPay": 676550, "exercisedValue": 0, "unexercisedValue": 458979}, {"maxAge": 1, "name": "Dr. Peter K. Kaiser M.D.", "age": 57, "title": "Chief Development Officer", "yearBorn": 1967, "fiscalYear": 2024, "totalPay": 698866, "exercisedValue": 0, "unexercisedValue": 669070}, {"maxAge": 1, "name": "Mr. Donald  Notman Jr.", "title": "CFO, COO & Principal Accounting Officer", "fiscalYear": 2024, "totalPay": 679770, "exercisedValue": 0, "unexercisedValue": 90888}, {"maxAge": 1, "name": "Dr. Peter K. Jarrett Ph.D.", "age": 67, "title": "Chief Technical Officer", "yearBorn": 1957, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. William S. Slattery Jr.", "title": "Vice President of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Todd D.C. Anderman J.D.", "age": 42, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1982, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. William H. Ransone II", "title": "Vice President of Global Sales & Marketing", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Barry  Rubenstein M.S.", "title": "Chief Human Resources Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Steve  Meyers", "title": "Chief Commercial Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 8, "compensationRisk": 10, "shareHolderRightsRisk": 7, "overallRisk": 10, "governanceEpochDate": 1759276800, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 11.44, "open": 11.64, "dayLow": 11.46, "dayHigh": 11.78, "regularMarketPreviousClose": 11.44, "regularMarketOpen": 11.64, "regularMarketDayLow": 11.46, "regularMarketDayHigh": 11.78, "payoutRatio": 0.0, "beta": 1.443, "forwardPE": -11.264706, "volume": 1601372, "regularMarketVolume": 1601372, "averageVolume": 2719943, "averageVolume10days": 2523540, "averageDailyVolume10Day": 2523540, "bid": 11.45, "ask": 11.52, "bidSize": 7, "askSize": 6, "marketCap": 2434779648, "fiftyTwoWeekLow": 5.785, "fiftyTwoWeekHigh": 13.85, "allTimeHigh": 44.19, "allTimeLow": 1.995, "priceToSalesTrailing12Months": 42.968723, "fiftyDayAverage": 12.1519, "twoHundredDayAverage": 9.425475, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 1685010048, "profitMargins": 0.0, "floatShares": 150272713, "sharesOutstanding": 211904239, "sharesShort": 13585178, "sharesShortPriorMonth": 15279147, "sharesShortPreviousMonthDate": 1757894400, "dateShortInterest": 1760486400, "sharesPercentSharesOut": 0.0641, "heldPercentInsiders": 0.0273, "heldPercentInstitutions": 0.74404, "shortRatio": 3.79, "shortPercentOfFloat": 0.0643, "impliedSharesOutstanding": 213164502, "bookValue": 1.769, "priceToBook": 6.495195, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -216748000, "trailingEps": -1.26, "forwardEps": -1.02, "enterpriseToRevenue": 29.737, "enterpriseToEbitda": -7.1, "52WeekChange": 0.010554075, "SandP52WeekChange": 0.16625166, "quoteType": "EQUITY", "currentPrice": 11.49, "targetHighPrice": 31.0, "targetLowPrice": 14.0, "targetMeanPrice": 21.91667, "targetMedianPrice": 20.5, "recommendationMean": 1.41667, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 12, "totalCash": 391134016, "totalCashPerShare": 2.248, "ebitda": -237316000, "totalDebt": 76939000, "quickRatio": 9.827, "currentRatio": 10.095, "totalRevenue": 56664000, "debtToEquity": 25.15, "revenuePerShare": 0.335, "returnOnAssets": -0.31137, "returnOnEquity": -0.63413, "grossProfits": -121314000, "freeCashflow": -115412872, "operatingCashflow": -175896992, "revenueGrowth": -0.181, "grossMargins": -2.14094, "ebitdaMargins": 0.0, "operatingMargins": -5.02571, "financialCurrency": "USD", "symbol": "OCUL", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Ocular Therapeutix, Inc.", "longName": "Ocular Therapeutix, Inc.", "corporateActions": [], "postMarketTime": 1761337220, "regularMarketTime": 1761336000, "exchange": "NGM", "messageBoardId": "finmb_41955650", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "priceEpsCurrentYear": -8.0537195, "fiftyDayAverageChange": -0.6619005, "fiftyDayAverageChangePercent": -0.05446889, "twoHundredDayAverageChange": 2.0645247, "twoHundredDayAverageChangePercent": 0.21903667, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.4 - Strong Buy", "cryptoTradeable": false, "regularMarketChangePercent": 0.437065, "regularMarketPrice": 11.49, "marketState": "CLOSED", "postMarketChangePercent": 0.0, "postMarketPrice": 11.49, "postMarketChange": 0.0, "regularMarketChange": 0.0500002, "regularMarketDayRange": "11.46 - 11.78", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 2719943, "fiftyTwoWeekLowChange": 5.705, "fiftyTwoWeekLowChangePercent": 0.9861711, "fiftyTwoWeekRange": "5.785 - 13.85", "fiftyTwoWeekHighChange": -2.3600006, "fiftyTwoWeekHighChangePercent": -0.17039715, "fiftyTwoWeekChangePercent": 1.0554075, "earningsTimestamp": 1754397000, "earningsTimestampStart": 1762777800, "earningsTimestampEnd": 1762777800, "earningsCallTimestampStart": 1754395200, "earningsCallTimestampEnd": 1754395200, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -1.26, "epsForward": -1.02, "epsCurrentYear": -1.42667, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1406295000000, "displayName": "Ocular Therapeutix", "trailingPegRatio": null, "__fetch_time": "2025-10-25"}]